Noxopharm’s Sofra Platform Science Published in Top Immunology Journal

Noxopharm Ltd. ( (AU:NOX) ) has issued an announcement.

Noxopharm has announced that the breakthrough science underpinning its Sofra platform has been published in Nature Immunology, a leading peer-reviewed journal in the field. The paper, led by Professor Michael Gantier of the Hudson Institute with contributions from Noxopharm staff and international collaborators, details a newly discovered anti-inflammatory mechanism that protects against autoimmune disorders.

The research explains how specific RNA fragments can modulate immune sensors TLR7 and TLR8, enabling the development of novel therapeutics such as Noxopharm’s SOF-SKN candidate for autoimmune skin conditions. Endorsement from prominent U.S. oligonucleotide expert Professor Arthur Krieg and the journal’s prestige bolster the scientific credibility of Sofra, potentially enhancing Noxopharm’s industry profile and attracting greater interest from partners and investors as it advances its drug pipeline for diseases like lupus, psoriasis, diabetes and rheumatoid arthritis.

The most recent analyst rating on (AU:NOX) stock is a Hold with a A$0.06 price target. To see the full list of analyst forecasts on Noxopharm Ltd. stock, see the AU:NOX Stock Forecast page.

More about Noxopharm Ltd.

Noxopharm Limited is a clinical-stage Australian biotechnology company focused on discovering and developing novel treatments for cancer and inflammatory diseases. Its work centres on two proprietary platforms, Sofra for inflammation, autoimmunity, mRNA drug enhancement and oncology, and Chroma for oncology, targeting large and growing global markets in autoimmune disease and immuno-oncology.

Average Trading Volume: 142,736

Technical Sentiment Signal: Strong Sell

Current Market Cap: A$17.24M

See more insights into NOX stock on TipRanks’ Stock Analysis page.